Dendritic Cells and Autoimmunity


Autoimmune responses can arise because the repertoire of both T- and B-cell receptors, which allows recognition of pathogens, may contain receptors recognizing self-components. Ideally, autoreactive lymphocytes should be destroyed in the thymus during negative selection and induction of autoimmunity should be controlled. However, a great number of self-reactive lymphocytes escape thymic negative selection processes and form a peripheral pool of potentially autoimmune disease-mediating lymphocytes. On the other hand, self-tissues and -cells are routinely destroyed in our body and thus self-antigens are available in situ. If self-reactive lymphocytes are not completely destroyed in thymus by negative selection, autoantigens may activate these lymphocytes, and the feature of autoimmunity is developed. Thus, the autoimmune process is a normal phenomenon of living organisms. To block the activities of these autoreactive lymphocytes and minimize clinically apparent autoimmune diseases, another mechanism is active in situ. A population of tolerogenic immunocytes (T-regulatory cells) is present in our body. When these lymphocytes also fail to block progression of an autoimmune process, the pathological consequences of autoimmunity become manifest. It is therefore important to clarify the mechanisms leading to the initial activation of self-reactive lymphocytes that induce and sustain the autoimmune response. Also, insights are required regarding the causes underlying the inability of tissue-derived dendritic cells (DCs) to induce immune tolerance to self-antigens. In addition, another population of DCs, called regulatory DCs, should downregulate the autoimmune processes.


Autoimmune Disease Primary Biliary Cirrhosis Immune Tolerance Primary Biliary Cirrhosis Patient Human Autoimmune Disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Recommended Readings

  1. Feili-Hariri M, Flores RR, Vasquez AC, Morel PA (2006) Dendritic cell immunotherapy for autoimmune diabetes. Immunol Res 36:167–173CrossRefPubMedGoogle Scholar
  2. Hardin JA (2005) Dendritic cells: potential triggers of autoimmunity and targets for therapy. Ann Rheum Dis 64(suppl) 4:86–90Google Scholar
  3. Kuwana M (2002) Induction of anergic and regulatory T cell by plasmacytoid dendritic cells and other dendritic cell subsets. Hum Immunol 63:1156–1163CrossRefPubMedGoogle Scholar
  4. Ludewig B, Krebs P, Junt T, et al (2003) Dendritic cell homeostasis in the regulation of self-reactivity. Curr Pharm Design 9:221–231CrossRefGoogle Scholar
  5. Manuel SL, Rahman S, Wigdahl B, Khan ZK, Jain P (2007) Dendritic cells in autoimmune diseases and neuroinflammatory disorders. Front Biosci 12:4315–4335CrossRefPubMedGoogle Scholar
  6. Mehling A, Beissert S (2003) Dendritic cells under investigation in autoimmune disesases. Crit Rev Biochem Mol Biol 38:1–21CrossRefPubMedGoogle Scholar
  7. Penna G, Giarratana N, Amuchastegui S, Mariani R, Daniel KC, Adorini L (2005) Manipulating dendritic cells to induce regulatory T cells. Microbes Infect 7:1033–1039CrossRefPubMedGoogle Scholar
  8. Tarner IH, Fathman CG (2006) Does our current understanding of the molecular basis of immune tolerance predict new therapies for autoimmune disease? Nat Clin Pract Rheumatol 2:491–499CrossRefPubMedGoogle Scholar
  9. Thomson AG, Thomas R (2002) Induction of immune tolerance by dendritic cells: implications for preventative and therapeutic immunotherapy of autoimmune disease. Immunol Cell Biol 80:509–519CrossRefGoogle Scholar
  10. Xiao BG, Huang YM, Link H (2006) Tolerogenic dendritic cells: the ins and outs of outcome. J Immunother 29:465–471CrossRefPubMedGoogle Scholar

Copyright information

© Morikazu Onji and Sk. Md. Fazle Akbar 2008

Personalised recommendations